... Inflammatory Diseases

Home About the ZPM ... Inflammatory Diseases

Personalized treatment

In the diagnosis and therapy of inflammatory diseases there are promising innovative approaches. Our goal is to determine the best therapy option for each individual patient at an early stage of the disease. Often, several organs are affected and the disease cannot be assigned to one specific medical field of expertise. In order to find the best therapeutic strategy for each patient we combine the disciplines of dermatology, gastroenterology and rheumatology in the Molecular Inflammation Boards. 


  • Innovative advanced diagnostics
  • Determination of the best first-line or last-line therapy on the basis of advanced diagnostics
  • Inclusion in clinical studies
  • Use of medication outside of the actual approval (off label) when the diagnostic profile is suitable
  • Identification of possible resistance factors to molecular therapy

Molecular Inflammation Boards

In the Molecular Inflammation Boards, specialists from various medical and scientific disciplines discuss together with diagnosticians the findings of each patient. The board's task is to find an optimal first-line therapy for inflammatory diseases involving multiple organs for which there is no guideline-based therapy option available. In addition, the Molecular Inflammation Boards also discuss patients for whom guideline-based treatment was unsuccessful in order to identify last-line therapy options. 

With the help of advanced diagnostics, markers relevant for individual therapy may be identified. Furthermore, the board may consider patient enrollment in clinical studies. 

The board's recommendation serves only as decision support for the attending physician. The attending physician discusses the further therapy decision with the patient and initiates the therapy. 

. .

What condition are currently discussed?

The Molecular Inflammation Boards are still in the development phase. Primarily, the Molecular Inflammation Boards discuss patients with advanced psoriasis, psoriatic arthritis, spondyloarthritis, or severe inflammatory bowel disease. Further disease entities will be added gradually. There is a constant harmonization between the sites which ensures a high level of quality and standardized treatment at the ZPMs.


Dr. Henriette Bertemes
Coordination ZPM Inflammation
Phone: +49 761 270-34051
Fax: +49 761 270-9634510
E-Mail:  henriette.bertemes@uniklinik-freiburg.de

Dr. Alica Linnebacher
Coordination ZPM Inflammation
Phone: +49 6221 56-38595
Fax: +49 6221 56-8099
E-Mail: alica.linnebacher@med.uni-heidelberg.de

Dr. Fee Schmitt
Coordination ZPM Inflammation
Phone: + 49 70712981239
Fax: +49 7071292727
E-Mail: fee.schmitt@med.uni-tuebingen.de

Dr. Michaela Reichenzeller
Coordination ZPM Inflammation
Phone; +49 731 500-44830
Fax; +49 731 500-44665
E-Mail: michaela.reichenzeller@uniklinik-ulm.de

Impressum | Datenschutz | Cookie-Einstellungen